Novo Nordisk AS's cash flow for dividends for the
three
months ended in Mar. 2026 was MXN-98,491 Mil. Its cash flow for dividends for the trailing twelve months (TTM) ended in Mar. 2026 was MXN-146,053 Mil.
Note: A negative number here means the payment of dividends. When pays more dividends, the absolute value gets bigger.
Novo Nordisk AS's quarterly payment of dividends
declined
from Sep. 2025 (MXN-48,069 Mil) to Dec. 2025 (MXN0 Mil) but then
increased
from Dec. 2025 (MXN0 Mil) to Mar. 2026 (MXN-98,491 Mil).
Novo Nordisk AS's annual payment of dividends
increased
from Dec. 2023 (MXN-78,893 Mil) to Dec. 2024 (MXN-129,256 Mil) and
increased
from Dec. 2024 (MXN-129,256 Mil) to Dec. 2025 (MXN-146,123 Mil).
Novo Nordisk AS Cash Flow for Dividends Related Terms
Novo Nordisk AS Cash Flow for Dividends Historical Data
* Premium members only.
The historical data trend for Novo Nordisk AS's Cash Flow for Dividends can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Novo Nordisk AS Cash Flow for Dividends Calculation
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.
Cash Flow for Dividends for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN-146,053 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Cash Flow for Dividends of MXN-146,053 Mil mean?
Novo Nordisk AS (MEX:NOVOBN) has a Cash Flow for Dividends of MXN-146,053 Mil as of Mar. 2026. Cash Flow for Dividends represent the amount a company pays as dividends for a specific accounting period. View historical data for Novo Nordisk AS and its competitors.
Is Novo Nordisk AS's Cash Flow for Dividends too high?
Novo Nordisk AS's current Cash Flow for Dividends is MXN-146,053 Mil. Overall, Novo Nordisk AS has a GF Score™ of 79/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Novo Nordisk AS's Cash Flow for Dividends compare to LLY and JNJ?
Novo Nordisk AS's Cash Flow for Dividends of MXN-146,053 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Flow for Dividends for a Drug Manufacturers company?
A good Cash Flow for Dividends depends on the Drug Manufacturers industry context. However, Cash Flow for Dividends should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Flow for Dividends mean?
A high Cash Flow for Dividends can signal that a stock is expensive relative to its fundamentals. Cash Flow for Dividends represent the amount a company pays as dividends for a specific accounting period. View historical data for Novo Nordisk AS and its competitors. Novo Nordisk AS's current Cash Flow for Dividends is MXN-146,053 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Novo Nordisk AS stock overvalued right now?
Based on GuruFocus' analysis, Novo Nordisk AS (MEX:NOVOBN) is currently considered Significantly Undervalued. The stock's GF Value™ is MXN2,387.36, compared to a current price of MXN810.00 — trading 66.1% below its estimated fair value. The current Cash Flow for Dividends is MXN-146,053 Mil. Novo Nordisk AS's overall GF Score™ is 79/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Flow for Dividends calculated?
Cash Flow for Dividends is calculated from a company's financial statements. For Novo Nordisk AS (MEX:NOVOBN), the current Cash Flow for Dividends is MXN-146,053 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Novo Nordisk AS (MEX:NOVOBN) Overvalued in 2026?
Based on GuruFocus' analysis, Novo Nordisk AS stock appears to be undervalued.
The current stock price of MXN810.00 is trading 66.1% below its estimated GF Value™ of MXN2,387.36.
GuruFocus considers Novo Nordisk AS to be Significantly Undervalued.
Key valuation signals for MEX:NOVOBN:
Cash Flow for Dividends: MXN-146,053 Mil
GF Value™: MXN2,387.36 vs. price of MXN810.00 (66.1% below fair value)
No single metric tells the full story. See the MEX:NOVOBN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
79GF Score
Get the complete analysis for MEX:NOVOBN
Cash Flow for Dividends is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:NOVOBN has been successfully added to your 
